ABSTRACT
No disponible
Subject(s)
Humans , Male , Adult , Pneumonia/complications , Pneumonia/drug therapy , Pneumonia , Meningitis/complications , Meningitis/drug therapy , Endocarditis/drug therapy , Endocarditis/physiopathology , Endocarditis , Cephalosporins/therapeutic use , Radiography, Thoracic , Aortic Valve/pathology , Aortic Valve , Aortic Valve Insufficiency/complications , Aortic Valve Insufficiency/drug therapy , Aortic Valve InsufficiencyABSTRACT
La metformina es un antidiabético oral de la familia de las biguanidas que se utiliza ampliamente en el tratamiento de pacientes con diabetes de tipo 2. Sus principales efectos secundarios son alteraciones inespecíficas gastrointestinales (10-30%). La acidosis láctica es el efecto secundario más grave, por lo que no debe administrarse a los pacientes con insuficiencia renal, hepática o cardiovascular grave. Se ha descrito de forma excepcional hepatotoxicidad por este fármaco. Presentamos el caso clínico de una paciente con diabetes mellitus de tipo 2 e inicio reciente de tratamiento con metformina que desarrolló un cuadro de hepatotoxicidad grave que siguió una evolución posterior favorable (AU)
Metformin is an oral biguanide widely used in the management of patients with type 2 diabetes. It produces non-specific gastrointestinal symptoms in 10-30% of the patients. Lactic acidosis is the most serious side effect, so it must not be administered to patients with renal, liver, or heart insufficiency. Only a few cases of hepatotoxicity due to this drug have been documented. We report the case of a patient with type 2 diabetes mellitus and recent use of metformin who developed serious liver injury, followed by a favorable evolution (AU)
Subject(s)
Humans , Female , Aged , /complications , Metformin/toxicity , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/complicationsABSTRACT
Metformin is an oral biguanide widely used in the management of patients with type 2 diabetes. It produces non-specific gastrointestinal symptoms in 10-30% of the patients. Lactic acidosis is the most serious side effect, so it must not be administered to patients with renal, liver, or heart insufficiency. Only a few cases of hepatotoxicity due to this drug have been documented. We report the case of a patient with type 2 diabetes mellitus and recent use of metformin who developed serious liver injury, followed by a favorable evolution.
Subject(s)
Chemical and Drug Induced Liver Injury/etiology , Hypoglycemic Agents/adverse effects , Metformin/adverse effects , Aged , Female , HumansABSTRACT
Catastrophic antiphospolipid syndrome (CAPS) is extremely rare antiphospolipid syndrome (APS) variety associated to higher mortality. When heart involvement appears has worsening pronostic. We reported a CAPS case, possibily afterward sting wasp triggering, with acute heart failure during evolution. The patient died despite angiographic stents, anticoagulation, corticoids and plasmaphereses treatment carried out.
Subject(s)
Antiphospholipid Syndrome/complications , Heart Failure/etiology , Heart Failure/mortality , Acute Disease , Fatal Outcome , Female , Humans , Middle AgedABSTRACT
El síndrome antifosfolípido catastrófico (SAPC) es una variedad del síndrome antifosfolípido (SAP), altamente infrecuente, asociada a mayor mortalidad. La aparición de afectación cardiaca, todavía más infrecuente, empobrece el pronóstico del mismo. Exponemos un caso de SAPC, posiblemente secundario a una picadura de avispa. Durante la evolución desarrolló un shock cardiogénico que a pesar de coronariografía, implantación de stents además de tratamiento con corticoides, anticoagulación y plasmaféresis, le produjo la muerte
Catastrophic antiphospolipid syndrome (CAPS) is extremely rare antiphospolipid syndrome (APS) variety associated to higher mortality. When heart involvement appears has worsening pronostic. We reporteda CAPS case, possibily after ward sting wasp triggering, with acute heart failure during evolution. The patient died despite angiographic stents, anticoagulation, corticoids and plasmaphereses treatment carried out
Subject(s)
Humans , Female , Middle Aged , Antiphospholipid Syndrome/diagnosis , Antiphospholipid Syndrome/mortality , Shock, Cardiogenic/complications , Adrenal Cortex Hormones/therapeutic use , Plasmapheresis , Anticoagulants/therapeutic use , Abdominal Pain/diagnosis , Antibodies, Anticardiolipin , Myocardial Infarction/diagnosis , Myocardial Infarction/therapy , Heparin/therapeutic use , Abdominal Pain/etiology , Shock, Cardiogenic/diagnosis , Shock, Cardiogenic/mortality , Antiphospholipid Syndrome/complicationsABSTRACT
No disponible
